Key result
Alirocumab safely reduced LDL cholesterol but did not decrease coronary artery plaque volume progression at 1 year compared with placebo.
Why the study?
The safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation are not well established.
Does alirocumab reduce coronary artery plaque progression in adult heart transplant recipients on statin therapy?
RCT (n=114)
Double-blind
1:1
Yes
Does alirocumab reduce coronary artery plaque progression in adult heart transplant recipients on statin therapy?
Early PCSK9 inhibition with alirocumab safely reduces LDL cholesterol in heart transplant recipients but does not prevent short-term coronary plaque progression when added to statin therapy.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“At the end of the day, the contributions towards development of CAV in our heart transplant patients from the traditional risk factors such as hyperlipidemia may be fairly modest. Although we want to optimize metabolic health to help our patients survive and thrive, maybe a simple lowering of LDL, at least in the short term, is not going to have a huge impact.”
“These results support PCSK9 inhibitors for patients who have high LDL cholesterol levels in conjunction with statin therapy, however, we need more studies testing treatment with PCSK9 inhibitors with longer term follow-up with more participants to confirm if PCSK9s can reduce the development of cardiac allograft vasculopathy.”
“This was lower than we anticipated and lower than previous studies had shown, and I think a reflection of the aggressive statin therapy that our participants received in the study.”
Alirocumab addition to statins not warranted for plaque control post-transplant; challenges PCSK9 inhibitor benefit on allograft vasculopathy progression.
BACKGROUND: Cardiac allograft vasculopathy is an important cause of mortality after heart transplantation (HT). Dyslipidemia is a major contributor to the development of cardiac allograft vasculopathy. The safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and to prevent cardiac allograft vasculopathy early after HT are not well established. METHODS: In this investigator-initiated, prospective, multicenter, double-blind randomized trial, participants were randomized early after HT to receive either alirocumab or placebo in addition to rosuvastatin. Before randomization and at 1 year, all participants underwent invasive coronary assessment, including angiography, fractional flow reserve, coronary flow reserve, the index of microcirculatory resistance, and intravascular ultrasound with near-infrared spectroscopy. Lipid values were assessed at baseline and at prespecified intervals. The primary end point was the change in coronary artery plaque volume from baseline to 1 year after HT based on serial intravascular ultrasound. RESULTS: A total of 114 HT recipients were included (57 assigned to alirocumab and 57 assigned to placebo). Baseline characteristics were well matched between the 2 groups. The low-density lipoprotein cholesterol levels decreased significantly from baseline to 1 year in the alirocumab arm (72.7±31.7 to 31.5±20.7 mg/dL; P <0.001) and did not change with placebo (69.0±22.4 to 69.2±28.1 mg/dL; P =0.92). Plaque volume increased numerically in both groups from baseline to 12 months (alirocumab, 176.3±95.2 to 184.5±105.4 mm³; P =0.23; placebo 173.7±96.7 to 183.1±109.8 mm 3 ; P =0.15). The change in plaque volume (mean difference in differences) did not differ between groups (1.01 [0.89–1.14]; P =0.86). Fractional flow reserve, coronary flow reserve, and the index of microcirculatory resistance did not change significantly with the addition of alirocumab. There were no significant adverse events related to alirocumab. CONCLUSIONS: Proprotein convertase subtilisin/kexin 9 inhibition with alirocumab in addition to statin therapy early after HT safely lowers low-density lipoprotein cholesterol but did not reduce coronary artery plaque progression after 1 year compared with rosuvastatin alone in patients with a low baseline low-density lipoprotein cholesterol. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03537742.
No takes yet. Share an insight, caveat, or question.
Fearon et al. (2025) conducted an RCT in Cardiac allograft vasculopathy (n=114). Alirocumab vs. Matching placebo was evaluated on Change in coronary artery plaque volume from baseline to 1 year after HT based on serial intravascular ultrasound (Mean difference 1.01, 95% CI 0.89-1.14, p=0.86). Alirocumab safely reduced LDL cholesterol but did not decrease coronary artery plaque volume progression at 1 year compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: